#285 Should a ‘flozin be chosen to play a part for a failing heart?
CLINICAL QUESTION
What is the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with chronic heart failure with reduced ejection fraction?
BOTTOM LINE
SGLT2i reduce mortality, heart failure hospitalizations, and improve quality of life when added to other medications in patients with heart failure with reduced ejection fraction, with or without diabetes. For every 100 patients treated with an SGLT2i for ~1.5 years, ~2 fewer will die, ~4 fewer will be hospitalized for heart failure, and ~7 will have improved quality of life (by 8 months) compared to placebo.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
Two industry-funded, randomized, placebo-controlled trials1,2 of patients with heart failure and ejection fraction ≤40% (mainly NYHA class 2-3, 47% with diabetes, average systolic blood pressure 122 mm Hg, 65% on combination betablocker/renin-angiotensin system blocker/mineralocorticoid receptor antagonist3). Results statistically different unless indicated.
- DAPA-HF:1 4744 patients, dapagliflozin 10mg daily.
- At 18 months:
- Mortality: 11.6% versus 13.9% (placebo), number needed to treat (NNT)=44.
- Heart failure hospitalization: 9.7% versus 13.4% (placebo), NNT=27.
- At 8 months:
- 58.3% versus 50.9% (placebo) achieved minimal important improvement in quality of life (≥5 points on 100-point scale), NNT=14.
- Adverse events: No difference.
- At 18 months:
- EMPEROR-Reduced:2 3730 patients, empagliflozin 10mg daily. At 16 months:
- Mortality: 13.4% versus 14.2% (placebo), not statistically different.
- Heart failure hospitalization: 13.2% versus 18.3% (placebo), NNT=20.
- Adverse events:
- Genital infections: 1.7% versus 0.6% (placebo), NNH=91.
- One meta-analysis4 including both trials:
- Reduction in mortality (NNT=61) and heart failure hospitalization (NNT=24).
- Similar efficacy in those with or without diabetes, and with or without sacubitril-valsartan.
- SGLT2i efficacy comparable to other heart failure medications:5,6
- Mortality: Relative risk reduction ~13% (others ~16-35%).
- Heart failure hospitalization: Relative risk reduction ~30% (others ~20-35%).
- Unlike other heart failure medications, SGLT2i do not seem to cause significant hypotension or electrolyte abnormalities.1,2,4
- Canadian guidelines7 recommend SGLT2i for patients with “mild to moderate” heart failure, though sequence not specified (e.g. whether to consider SGLT2i prior to sacubitril-valsartan).
- Splitting empagliflozin 25mg in half=12.5 mg (trial dose=10 mg) cuts cost in half (to ~$560/year).8
Latest Tools for Practice
#353 - Turn Down the Heat! Can non-hormonal drugs improve vasomotor symptoms in menopause? (Free)
Do non-hormonal medications improve menopausal vasomotor symptoms?
#352 Do-It-Yourself Hearing Aids (Free)
Do self-fitted hearing aids improve hearing for adults with mild to moderate-severe hearing loss?
#351 Flaked out? Topical treatment for seborrheic dermatitis (Free)
How effective are topical treatments for adult facial or scalp seborrheic dermatitis?
